Cancer affects approximately 1 in 3 individuals. An individual's susceptibility to cancer is partly determined by environmental exposures and by the combination of inherited cancer susceptibility and resistance genes. Initial mapping of these low penetrance cancer susceptibility genes has been done in the mouse because human low penetrance genes are extremely difficult to find using traditional methods due to heterogeneity and interacting factors. Also, the choice of candidate genes for human association studies can miss the unknown or unexpected. Mouse models also have limitations; it can be difficult to identify causal polymorphisms in the mouse because linkage disequilibrium often extends across several genes. To exploit the strengths of both systems, we outline a cross-species strategy to identify human variants associated with increased cancer risk. This approach uses linkage analysis and haplotyping, allelic imbalance in tumors, and gene expression studies in the mouse, combined with association studies and tumor imbalance studies in humans to identify causal cancer susceptibility variants. Allelic variants in both mouse and human can then be used to better understand the mechanisms behind cancer risk and as targets for intervention.
INTRODUCTION
Human cancer susceptibility is in part attributable to the presence of rare mutations or polymorphisms in genes that have major effects on tumor growth or survival. Highpenetrance mutations in genes such as BRCA1 and BRCA2 are responsible for a proportion of cancers that show familial aggregation. However, the genetic basis of susceptibility to the majority of cancers that have no obvious familial aggregation is almost completely unknown (Ponder, 2000) . Mathematical modeling of human breast cancer susceptibility suggests that a high proportion of cancers (about 50%) occur in a relatively small proportion (12%) of highrisk women (Pharoah et al., 2002) . Currently, there is no consensus regarding the genetic model that can account for this increased risk, in particular whether it is caused by aggregation of multiple rare alleles in a subset of genes that have strong effects (multilocus/multiallele hypothesis), by combinations of common alleles with weak effects (common disease/common allele hypothesis) or by some combination of these models (Cardon & Bell, 2001; Wright and Hastie MD, 2001; Balmain et al., 2003; Botstein and Risch, 2003) . The detection of low penetrance genetic variants in studies of the human population has been fraught with difficulties. The genetic heterogeneity and variable etiology of carcinogenesis in humans has necessitated the collection of large numbers of DNA samples from cancer patients and control populations, with no guarantee that the methods presently available will allow the detection of the most important loci. The confirmation of the multilocus/ multiallele hypothesis will be extremely difficult using association analyses. While the common disease/common allele hypothesis should in principle be amenable to testing in human populations, in practice there will be major problems because of the number of genetic variants involved, and the complexity of their interactions. Our inability to quantify the variable levels of environmental carcinogens to which different individuals are exposed adds a further dimension of uncertainty to the resolution of these questions.
Mouse models offer one important approach to the study of these alternative models of susceptibility (Frankel, 1995; Balmain and Nagase, 1998; Balmain, 2002) . Studies on mice have revealed that tumor predisposition in different strains is controlled by multiple loci which control fundamental processes such as tumor growth rate, ability to stimulate angiogenesis, or the risk of malignant progression. Studies on mice, have led to the development of a number of very sophisticated genetic tools for the analysis of complex genetic traits, including recombinant inbred strains, recombinant congenic strains, and intra-or interspecific backcrosses. Using such approaches, a large number of resistance/susceptibility genes for cancers of all of the major tissue types including the lung, colon, and skin, have been mapped in the mouse (Nagase et al., 1995; Fijneman et al., 1996; van Wezel et al., 1996; van Wezel et al., 1999) . The genetic model that applies to studies of mouse tumor susceptibility is by definition the common disease/common variant model, by which combinations of common alleles control tumor predisposition. A mouse backcross population has only 1 or 2 alleles segregating at each locus, and specific combinations of these genetic variants determine the distribution of risk across the population. In addition, environmental risks can be added in a controlled manner for study. The tumor risk in a backcross or intercross population can vary over orders of magnitude: this enormous variation in phenotype is conferred by combinations of common alleles that in isolation have only weak or moderate effects.
An additional important feature of mouse genetics is the ability to detect interactions between genetic variants, leading to additive or synergistic effects in conferring cancer resistance. It has been shown that specific alleles at different loci, when inherited in combination in mice, exert much greater effects on tumor development than would be expected from their individual "strength" as tumor predisposition loci. Such genetic interactions have been originally demonstrated in plants, and more recently in recombinant congenic strains (Iakoubova et al., 2001; Tripodis et al., 2001) or in interspecific backcross mice (Nagase et al., 2001) . With the development of more sophisticated computational and bioinformatics tools, we should be able to identify many of these interactions, which in turn will provide important information on the biochemical and biological pathways these genes control. A related question that can best be analyzed using the mouse is the gene-environment link, which clearly is extraordinarily important in cancer predisposition, contributing up to 50% of the variance in susceptibility for most common tumors.
One drawback to using mice is that the resolution of quantitative trait locus (QTL) mapping that is normally attainable from linkage analysis of mouse backcross or intercross populations is quite low-about 10-30 cM, depending on the strength of the locus and the number of animals used in the cross (Nadeau et al., 2000) . A relatively large number of loci have been mapped for cancer or other diseases, however only a fraction of genes from those loci have been currently identified (Korstanje and Paigen, 2002) . One common way of identifying the critical gene at high resolution is to make congenic mice. In this approach, breeding transfers the susceptibility allele at a particular locus from one strain on to the genetic background of the other. This process can take FIGURE 1.-Strategy for identification of cancer susceptibility genes. Flow diagram of mouse/human cross-species strategy for low penetrance cancer susceptibility gene identification is outlined. several years, is very expensive, and frequently unsuccessful. The reasons for lack of success may be that the locus contains more than one gene, making identification of the functional variant difficult because the genes become separated as breeding progresses. Alternatively, many of these alleles require interactions with variant alleles of completely separate genes at other chromosomal locations in order to exert their effects.
Due to the problems in both of these systems, we outline one approach to the identification of lower penetrance cancer susceptibility genes that uses the strengths from the human and the mouse (Figure 1 ). The first step is to identify target loci. This can be done through a combination of linkage mapping of cancer susceptibility genes using mouse strains, followed by refinement of the locus through haplotyping using outbred mouse strains and array comparative genomic hybridization (aCGH) of tumors in the mouse. aCGH data from the orthologous locus in humans can also be used to identify any common targets and, in some cases, to narrow down a candidate locus. Genomic loci and genes to target can be prioritized according to the frequency of somatic changes involving a locus, the strength of association with susceptibility and human relevance. Once a locus is sufficiently refined, candidate genes from the locus can be identified through expression studies in normal and mouse tissues and allelic specific changes in tumors. Human tumor expression analyses can also be used to prioritize candidate genes. The last step is to identify the causal cancer susceptibility gene and variant. This is done through a "back-and-forth" process between the mouse and human using mutation and single nucelotide polymorphism (SNP) screening, allelic imbalance studies in human tumors, association studies in human populations and 28 EWART-TOLAND ET AL TOXICOLOGIC PATHOLOGY functional studies of potential variants. Finally, the biological mechanism of the polymorphism can be addressed in a mouse model.
Identification of Target Loci
We previously identified 13 loci by QTL analysis that control skin tumor susceptibilityin crosses between outbred Mus spretus and inbred strains of Mus musculus (unpublished results, Nagase et al., 1995 Nagase et al., , 1999 . Our use of outbred Mus spretus rather than the inbred strains used in most laboratories, enable us to use a combination of standard linkage analysis and haplotyping to refine the localizations of several QTLs in this backcross. Information on shared haplotypes in outbred populations of humans or experimental animals has been used to refine the locations of potential disease susceptibility genes. We constructed haplotypes for several regions containing susceptibility loci using the variation in microsatellite lengths between the spretus alleles in the outbred colony. We have been able to exploit this approach to reduce the size of the intervals most likely to contain QTLs from 10-20 cM to around 1-2 cM for three separate loci on chromosomes 1, 2 (Skts13) and 7.
To determine which loci should be prioritized for future study, we examined the orthologous locus in humans.Skts13, shows strong linkage and lies within a region of distal mouse chromosome 2 that is orthologous to a locus on human chromosome 20q13.2. Human 20q13.2 shows frequent amplification in a variety of tumor types including breast, colon, and ovarian cancer (Kallioniemi et al., 1994; Iwabuchi et al., 1995; Korn et al., 1999; Alberston et al. 2000; Tanner et al., 2000) . In addition, by linkage analyses, a susceptibility gene in the 20q13 region has been implicated in prostate cancer (Berry et al., 2000) . No strong candidate gene has as yet been identified. Because of the strong linkage and evidence for somatic involvement in humans, this locus had a strong likelihood of housing a cancer susceptibility gene in mouse and humans.
Identification of Candidate Genes
Once a locus has been mapped through linkage analysis and refined through haplotyping and tumor CGH studies, candidate genes from that locus can be identified. Since sequencing of both mouse and human genomes are complete, fairly complete genetic maps are available in both public and private databases and can be used to make lists of genes in a target region. We constructed a physical map of the distal part of chromosome 2 using the Celera database, and carried out sequence and expression analysis of candidate genes within the region (Ewart-Toland et al., 2003) . The orthologous candidate locus on human chromosome 20q13.2 is frequently amplified in human tumors and consists of at least 3 smaller subamplicons, each containing a putative driver gene for amplification, i.e., ZNF217 (encoding a putative Kruppel-like transcription factor), CYP24 (encoding vitamin D24 hydroxylase), and Aurora2, also known as Aurora2/Stk6 in mouse and STK15 in human (encoding a centrosome-associated kinase), respectively (Bischoff et al., 1998; Collins et al. 1998; Albertson et al. 2000) . Based on CGH and functional data, these 3 genes were good candidate genes for further testing in mouse and human tumor tissues. Expression studies of these 3 candidates showed that there was only 1 gene, Stk6, show-ing allele-specific expression in normal tissues from Spretus X Musculus F1 hybrid mice. The musculus allele was consistently overexpressed, and furthermore the same allele was preferentially amplified in tumors from F1 hybrid mice. Based on mouse expression data, the candidate gene, Stk6, became our top candidate for more intensive screening.
Confirmation of Potential Cancer Susceptibility Genes
A difficult part of any mapping study is the confirmation of a candidate gene. In mice there is high linkage disequilibrium such that identification of causal mutations or polymorphisms is problematic. Human populations have relatively low linkage disequilibrium but are extremely heterogeneous which can be exploited to help find causal variants. Our proposed strategy for identification of low penetrance cancer susceptibility genes uses a "back-and-forth" approach of using information about the candidate gene gleaned from one species to better focus the testing of the same candidate gene in the other.
Based on our mapping and expression data, Stk6 was a top candidate gene for the locus on chromosome 2. Sequence analysis of this gene in the mouse did not yield any polymorphisms that fit the mapping data. Therefore, we decided to look at variants in this gene in human populations using association studies. Association analyses using DNA samples from population-based case-control or cohort studies are a powerful tool for the detection of SNPs that confer relatively weak effects on tumor susceptibility (Cardon and Bell, 2002) . One of the drawbacks of large association studies is repeatability (Hirshhorn, 2002; Colhoun, 2003) , although lack of replication of previous studies may frequently be due to poor statistic power in follow-up experiments (Lohmueller et al., 2003) . Therefore, the choice of candidate genes for testing is critical. In our model the choice of candidate genes for human association studies was initially guided by 2 sets of criteria: 1) evidence for the presence of a mouse susceptibility locus from linkage analysis and allele-specific expression in mouse tumors, 2) evidence from human tumor analysis for somatic events involving the syntenic human region.
For our minimal interval on human chromosome 20q13, we initially carried out association studies using DNA samples from breast, and prostate cancer patients of Caucasian origin and matched controls using a series of polymorphisms that were identified in the Aurora2/STK15, ZNF217, and CYP24 genes. Association studies revealed that of 7 polymorphisms tested, only 1 polymorphism in STK15 showed a modest increase in cancer risk in two cancer types (breast and prostate, Ewart-Toland et al., 2003) . However the results in this population did not reach the significance levels required for acceptance as a true susceptibility gene (Dahlman et al. 2002; Cardon and Bell, 2001) .
Many such association studies with weak or low penetrance genes suffer from the fact that the overall effects are difficult to detect and are consequently notoriously difficult to replicate. We already know from mouse genetic analysis of QTLs that genetic background effects are extremely powerful, and can mask or uncover the effects of susceptibility alleles (Nagase et al., 2001) . We believe that the merely suggestive results obtained from many human association studies using SNPs, is due to the failure to take account of interacting genes. Human association studies may therefore only be Vol. 32(Suppl. 1), 2004 GENETICS OF CANCER SUSCEPTIBILITY 29 FIGURE 2.-Genetic changes at cancer susceptibility genes. Cancer susceptibility genes may drive copy number changes in tumors such that cancer resistance alleles may be lost through deletion and cancer susceptibility genes may show gain through amplification or mitotic loss and recombination resulting in loss of heterozygosity (LOH). These allele specific somatic losses and gains may be used to map cancer susceptibility genes. fruitful when we have a deeper knowledge of the interacting gene networks that buffer the effects of any single strong polymorphism.
Another parallel between mouse and human is allelespecific genetic events in tumors may be able to be used as a surrogate for large-scale association studies to detect low penetrance susceptibility genes. We have shown previously that several mouse skin tumor susceptibility loci exhibit allele-specific copy number changes in tumors (Nagase et al., in press; Figure 2) . To further test the candidacy of Stk6/STK15, we investigated the possibility that amplification of the SKT15 gene, which occurs in over 50% of colon cancers, might preferentially involve the STK15 allele associated with cancer susceptibility. Allelic imbalance studies of colon tumor DNA showed a majority of heterozygous samples with imbalance had increased copy number of the susceptible allele versus the common allele. These data suggest that variants in STK15 are involved in human cancer susceptibility.
FUTURE STUDIES
To definitively show that Stk6 is the cancer susceptibility gene mapping to distal chromosome 2, functional studies using the human variants as well as using our mouse models will need to be conducted. Any further insights into the function of Stk6/STK15 that are gleaned from the models can be tested in human tumors or cell lines. In addition to examining the potential effect of Stk6 in isolation, the mouse models can be used to identify any interacting genetic factors that can be tested as a network for cancer risk rather than in isolation.
SUMMARY
We have developed a cross-species approach for the identification of low penetrance cancer susceptibility genes. Identification of human cancer susceptibility genes would lead to a better understanding of the mechanisms involved in tumor initiation and progression, as well as to novel methods for prevention or treatment. Linkage analyses using outbred mouse models are an excellent way to identify fairly refined candidate loci. Tumor imbalance data, aCGH, and expression data from both human and mouse can be used to refine the selection of candidate genes mapping to the locus. Finally, going "back and forth" between mouse and human systems can aid in the identification of a causal variant in a candidate gene. Functional characterization of candidate variants and genetic interaction studies can then be completed in a mouse system guided by human biology.
